Evaluation of methylation pattern in promoter region of E-cadherin gene and its relation to tumor grade and stage in breast cancer

African Journal of Biotechnology

Volumn 10, Issue 10, 2011, Pages 1745-1751

  Shargh, Shohreh A ^a,b   Sakizli, Meral ^b   Farajnia, Safar ^c,d   Montazer Saheb, Soheila ^d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b Eylul University   (Turkey)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; E cadherin; Methylation pattern; Tumor grade; Tumor stage

Indexed keywords

UVOMORULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CDH1 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; FEMALE; GENE INACTIVATION; HUMAN; HUMAN TISSUE; METASTASIS; PROMOTER REGION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 79952688351     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Berx G, Roy VF (2001). The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 3(5): 289-293.
2. Berx G, Roy VF (2009). Involvement of members of the cadherin superfamily in cancer. Cold. Spring. Harb. Perspect. Biol. 1(6): a003129.
3. Bornman DM, Mathew S, Alsruhe J, Herman JG, Gabrielson E (2001). Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly Individuals. Am. J. Pathol. 159(3): 831-835.
4. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, Huntsman D (2004). Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J. Med. Genet. 41(7): 508-517.
5. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman GJ, Velculescu V, Schuebel KE, Ahuja N, Baylin SB (2008). Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis PLoS. Med. 5(5): e114.
6. Chao YL, Shepard CR, Wells A (2010). Breast carcinoma cell reexpress E-cadherin during mesanchymal to epithelial reverting transition. Mol. Cancer, 9: 179-196.
7. Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, Nesline MK, Ambrosone CB, Karpf AR (2009). Association between global DNA hypomethylation in leukocytes and risk of Breast Cancer. Carcinogenesis, 30(11): 1889-1897.
8. Conerly M, Grady WM (2010). Insights into the role of DNA methylation in disease through the use of mouse models. Dis. Model. Mech. 3(5-6): 290-297.
9. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, Brunner N, Foekens JA, Schmitt M (2009). Methylated genes as new cancer biomarkers. Eur. J. Cancer, 45(3): 335-346.
10. Ehdaie B, Theodorescu D (2008). Molecular markers in transitional cell carcinoma of the Bladder: new insights into mechanisms and prognosis. Indian. J. Urol. 24(1): 61-67.
11. Esteller M (2005). Dormant hyper methylated tumor suppressor genes: questions and answers. J. Pathol. 205(2): 172-180.
12. Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC Jr, Yu Y (2010). Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancer. BMC Cancer, 10: 378-388.
13. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. PNAS, 89(5): 1827-1831.
14. Goldstein NS (2002). Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases? Am. J. Clin. Pathol. 118(3): 425-434.
15. Hiraki M, Kitajima Y, Sato S, Nakamura J, Hashiguchi K, Noshiro H, Miyazaki K (2010). Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. World J. Gastroenterol. 16(3): 330-338.
16. Hunter KW, Alsarraj J (2009). Gene expression profiles and breast cancer metastasis: a genetic perspective. Clin. Exp. Metastasis, 26(6): 497-503.
17. Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, Stain S, Chapman WC, Washington MK, Willis J, Markowitz SD, Grady WM (2006). CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes. Chromosomes Cancer, 45(8): 781-789.
18. Kordi-Tamandari DM, Moazeni-Roodi AK, Rigi-Ladiz MA, Hashemi M, Birjandian E, Torkmanzehi A (2010). Promoter hyper methylation and expression profile of MGMT and CDH1 genes in oral cavity cancer. Arch. Oral. Biol. 55(10): 809-814.
19. Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, Bittard H (2006). N-Cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin. Cancer Res. 12(9): 2780-2787.
20. Li SY, Rong M, Iacopetta B (2006). DNA hypermethylation in breast cancer and its with clinicopathological featurs. Cancer Lett. 237(2): 272-280.
21. Lo PK, Sukumar S (2008). Epigenomics and breast cancer. Pharmacogenomics, 9(12): 1872-1902.
22. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D (2007). Germ line E-cadherin mutations in familial lobular breast cancer. J. Med. Genet. 44(11): 726-731.
23. Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K (2006). The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in non small cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer, 106(10): 2190-2199.
24. Oyama T, Yasui Y, Tanaka T (2009). Breast cancer chemoprevention: Current Perspectives. Curr. Enzyme Inhib. 5: 198-208.
25. Pourabbas R, Farajnia S, Kimyai S, Mohammadnejad L, Johnson A, Nejatian T (2009). In vitro assessment of cytotoxicity of giomer on human gingival fibroblasts. Afr. J. Biotechnol. 8(20): 5522-5526.
26. Ribeiro-Filho LA, Franks J, Sasaki M, Shiina H, Li LC, Nojima D, Arap S, Carroll P, Enokida H, Nakagawa M, Yonezawa S, Dahiya R (2002). CpG hyper methylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol. Carcinog. 34(4): 187-198.
27. Rodenhiser D, Mann M (2006). Epigenetics and human disease: translating basic biology Into clinical applications. CMAJ, 174(3): 341-348.
28. Sahin AA, Guray M, Hunt KK (2009). Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer. Arch. Pathol. Lab. Med. 133(6): 869-878.
29. Varshochi R, Halim F, Sunters A, Alao JP, Madureira PA, Harts SM, Ali S, Vigushin DM, Coombes RC, Lam EW (2005). ICI182, 780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J. Biol. Chem. 280(5): 3185-3196.
30. Vesuna F, van Diest P, Chen JH, Raman V (2008). Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem. Biophys. Res. Commun. 367(2): 235-241.
31. Xia HH, Tischoff I, Tannapfel A (2008). DNA methylation in hepatocellular carcinoma. World J. Gastroenterol. 14(11): 1741-1748.